Female genital schistosomiasis (FGS) Accelerated Scale Together Package or The FAST Package, Madagascar
Madagascar is the world’s second-largest island country with 114 districts. Over 24 million in 106 districts are at risk of schistosomiasis (SCH) infection. Among these, 27 districts report the presence of S. haematobium and the risk of female genital schistosomiasis (FGS). This project strengthens Madagascar’s SCH control and elimination efforts through the FGS Accelerated Scale Together (FAST) Package, that is focused on raising awareness about FGS. The FAST Package is led by the Bruyère Research Institute (Canada), the University of Health and Allied Sciences (Ghana), and the Association K’olo Vanona (Madagascar).
Acceleration of elimination of onchocerciasis in Mali - towards high coverage and acceptability of mass drug administration amongst hard-to-reach populations
This mixed methods implementation research will guide the preparation of mass drug administration (MDA) for the elimination of onchocerciasis in the KA05 zone of Mali.
Treatment acceptability study pre-/post- mass drug administration using 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis in Belitung District, Indonesia
A mixed methods study will be carried out to understand factors that affect compliance with past and recent public health interventions in Belitung, Indonesia. Results from this study will assist the District Health Authority as they prepare to rollout a new treatment regimen for lymphatic filariasis.
Female Genital Schistosomiasis Accelerated Scale Together (FAST) package
The Female Genital Schistosomiasis Accelerated Scale Together (FAST) package, addressed a common sexual and reproductive health issue affecting women and girls in Sub-Saharan Africa.
Exploring patterns of non-participation across multiple health campaigns: an exploratory study using qualitative methods in Ghana and Indonesia
This study explored the potential that ‘never treatment’ or ‘zero dose’ is a household phenomenon that spans more than one health domain (Neglected Tropical Diseases, vaccines, bed net use, Covid-19 measures) in selected regions of Ghana and Indonesia.
Results reporting using stories of change
Global Affairs Canada (GAC) partnered with the Threads Lab to develop a methodology for the collection and analysis of stories of change as part of GAC’s efforts to better tell the results story for its investments in health and nutrition.
Fostering CDD Resilience and Well-Being: Strategic Adaptations to Promote Safe and Effective MDA and COVID-19 Response
As COVID-19 continued its global spread, national and local health systems urgently needed to mobilize resources to implement surveillance, contact tracing, community sensitization, and stigma reduction and treatment to mitigate transmission and bring the outbreak under control.
Impact evaluation of the pilot
Vanier Social Pediatrics Hub program
The Vanier Social Pediatrics Hub (VSP Hub) is a child-focused social pediatrics program designed to provide comprehensive health and social services, and support in accessing the social determinants of health to children in a geographic area which is amongst the poorest in Vanier, Ottawa, Ontario.
Opportunities and barriers to health campaign integration across Vitamin A, polio, immunisation, neglected tropical diseases and insecticide treated bed nets: voices from the field
In low and middle-income countries, health campaigns are used as a significant part of the strategy to address high-priority health areas, such as Neglected Tropical Diseases (NTDs), Malaria, Polio and other vaccine-preventable diseases (e.g., measles, yellow fever, typhoid, tetanus, meningitis, HPV), and nutrition (vitamin A).
Treatment acceptability study following the Community Based Safety Study of 2-drug (Diethylcarbamazine & Albendazole) versus 3-drug (Ivermectin, Diethylcarbamazine & Albendazole) Therapy for Lymphatic Filariasis in Papua New Guinea, Haiti, Fiji, Indonesia & India
The acceptability of a new combination treatment regimen for lymphatic filariasis (ivermectin, plus DEC and albendazole, or IDA) was assessed as part of a larger community-based safety study in Fiji, Haiti, India, Indonesia and Papua New Guinea.